Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
Published date:
12/15/2022
Excerpt:
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 2.2….Pembrolizumab, platinum, and fluorouracil may be offered as first-line treatment for patients with recurrent or metastatic HNSCC with a CPS < 1